Acanthamoeba Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs

Brian Shing,Mina Balen,James H. McKerrow,Anjan Debnath
DOI: https://doi.org/10.1080/14787210.2021.1924673
2021-05-19
Abstract:<span><b>Introduction</b>: <i>Acanthamoeba</i> encompasses several species of free-living ameba encountered commonly throughout the environment. Unfortunately, these species of ameba can cause opportunistic infections that result in <i>Acanthamoeba</i> keratitis, granulomatous amebic encephalitis, and occasionally systemic infection.<b>Areas covered</b>: This review discusses relevant literature found through PubMed and Google scholar published as of January 2021. The review summarizes current common <i>Acanthamoeba</i> keratitis treatments, drug discovery methodologies available for screening potential anti-<i>Acanthamoeba</i> compounds, and the anti-<i>Acanthamoeba</i> activity of various azole antifungal agents.<b>Expert opinion</b>: While several biguanide and diamidine antimicrobial agents are available to clinicians to effectively treat <i>Acanthamoeba</i> keratitis, no singular treatment can effectively treat every <i>Acanthamoeba</i> keratitis case. Efforts to identify new anti-<i>Acanthamoeba</i> agentsassays remain largely manual and would benefit from further automation development. Additionally, the existing literature on the effectiveness of various azole antifungal agents for treating <i>Acanthamoeba</i> keratitis is incomplete or contradictory, suggesting the need for a systematic review of all azoles against different pathogenic <i>Acanthamoeba</i> strains.</span>
pharmacology & pharmacy,infectious diseases,microbiology
What problem does this paper attempt to address?